By Tyson Sheridan 
The Growing Role of AI in Diagnostics
The medical technology field is being changed by Artificial Intelligence or AI, mostly in diagnostic areas of healthcare. At LSI Europe 2024, medical technology expert speakers described how AI has developed from a hype to a reality that is altering healthcare systems through the creation of clinical products that work in real clinical settings.
This panel consisted of senior leaders from multiple AI-enabled medical technology companies, with large numbers involved on the state-of-the-art of the technology of AI being applied to stroke detection, behavioral health assessments, and colorectal cancer screening, as well as other diagnostic areas of critical importance in the healthcare system.
All panelists shared their views regarding AI in the diagnostic area and stated the potential of AI to change the way that clinicians will do their jobs and provide patient care; however, they also made it clear that trusting AI to make clinical diagnoses, supplying the information necessary to make clinical diagnoses, incorporating AI into the clinical workflow, and understanding the real medical needs are crucial for long-term success.
Trust, Transparency, and Training Data
During the Europe panel at the medtech conference, one of the most important topics of discussion was the need for transparency in AI development. Experts at the medtech conference emphasized that the quality of training data has a direct impact on the accuracy, safety, and reliability of AI models, especially within healthcare environments where diagnostic systems are used across diverse patient populations and clinical settings.
Panelists highlighted that medtech innovators developing AI-powered healthcare solutions must be transparent about how their systems are trained, tested, and validated. According to insights shared through medtech intelligence discussions, AI tools that lack transparency may introduce bias or deliver inaccurate outcomes when applied outside their original intended use.
The discussion also reinforced the importance of inclusive and representative datasets. Medtech innovators were encouraged to prioritize diversity in clinical data not only to improve product performance, but also to align with evolving global regulatory expectations. Throughout the medtech conference, speakers noted that stronger data governance, transparency, and ethical AI development will play a critical role in the future of the medical technology sector.
Real-World Learning and Post-Market Validation
The second important topic addressed at the LSI Europe meeting was the value of post-marketing experience.
Commercial organizations need to keep track of their AI technologies after receiving approval and being introduced into the healthcare environment. Panelists suggested that no dataset can adequately represent all clinical manifestations; therefore it is essential to evaluate performance on an ongoing basis.
Most companies that produce artificial intelligence systems do so via controlled and inactive re-trainings (i.e., disconnected and pre-scheduled learning), not via free-form and unstructured in-use re-trainings (i.e. connected and scheduled breakdowns). Therefore, it provides a regulatory-friendly means for new medical technology companies to comply with current regulations while able to enhance their models over time.
As companies in the medical technology industry evolve, post-market validation will continue to be a higher priority as healthcare solutions that are based upon artificial intelligence technology begin to reach progressively larger and more diverse patient populations as well as healthcare systems.
Integration Into Existing Healthcare Infrastructure
Also stressed by the panel of experts is that integration into current clinical workflows is critical to the achievement of success for ai in diagnostics. Many hospitals and healthcare providers already have established means to communicate, use imaging technologies and utilize telehealth, so rather than replacing these technologies all together the successful partnerships that exist thus far between the ai industry and the medical technology industry typically involve incorporating ai capabilities into existing technologies that clinicians use on a daily basis. This not only reduces friction during implementation, but also increases the likelihood of adoption by hospitals and other healthcare providers. The panelists stated that the ai industry should remain focused on problems within medicine rather than developing excess infrastructure. By utilizing already established healthcare platforms, medical technology start ups should be able to expand more quickly and provide greater value to the industry as a whole.
Business Models That Support Adoption
The discussions were not only about the technology itself, but also emphasized the major role that business models play in helping encourage the adoption of AI technologies in healthcare.
Most of the medical providers have been slow to invest heavily into these new technologies, particularly due to the high initial costs associated with emerging technologies, thus making subscription and lease-based payment models more common within the medical technology markets.
Flexible pricing structures provide hospitals or medical clinics with the opportunity to evaluate and test an AI-based solution without exposing themselves to significant financial risk, while also providing a recurring source of revenue to the companies to help support continual development of the product, as well as ongoing service/support provided to its customers.
For innovators developing new products in the medtech area, complementary alignment between business strategies with clinically-based adoption will be key to long-term success.
Customer Success Before Rapid Scaling
A few panel members noted that aggressive growth should follow a high priority to your customer’s success. To develop new products for the med tech space, AI companies can benefit from using early adopters as an opportunity to learn about how their solutions work in real-life clinical settings. By getting feedback from physicians and making improvements in usability and workflows before moving into full-scale commercialisation assists companies in placing greater strength behind their products.
The panel participants talked about how med tech startups tend to have a different mix of skills among their customer success teams, including clinical, technical and business skills that help provide support to healthcare providers beyond the traditional sales model.
The emphasis on practical application is indicative of a larger trend within the med tech industry, where execution and usablility are just as important as new and innovative products.
Staying Focused on Real Medical Problems
At the MedTech 2023 conference, the significant takeaway was the necessity to focus on genuine healthcare needs instead of creating AI for the sake of AI. The participants agreed that companies should focus on technologies designed to address meaningful clinical issues and expand access to care for patients. AI will offer great opportunities for increased access to healthcare worldwide, particularly in countries with little access to diagnostic tools.
To create solutions that will produce a measurable result in health systems, medtech innovators must remain grounded in patient outcomes and clinical value. The panel discussion at LSI Europe 2023 also established that AI in diagnostics is no longer a theoretical concept; it is already causing disruption in various sectors of the MedTech industry, including imaging, oncology, behavioral health, and telehealth. However, developing a sustainable solution requires more than good algorithms; it necessitates transparency, responsible deployment, successful integration, and a substantial commitment to addressing the significant challenges facing the delivery of healthcare.